- Home
- GLSI
as 06-06-2025 1:36pm EST
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | STAFFORD |
| Market Cap: | 133.4M | IPO Year: | 2020 |
| Target Price: | $39.00 | AVG Volume (30 days): | 36.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.27 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.06 - $18.75 | Next Earning Date: | 05-20-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Greenwich LifeSciences Inc. (GLSI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Patel Snehal | GLSI | CEO and CFO | Apr 25 '25 | Buy | $9.88 | 3,600 | $35,568.00 | 5,570,602 | |
| Patel Snehal | GLSI | CEO and CFO | Apr 17 '25 | Buy | $8.98 | 5,400 | $48,492.00 | 5,570,602 | |
| Patel Snehal | GLSI | CEO and CFO | Apr 7 '25 | Buy | $9.10 | 3,600 | $32,760.00 | 5,570,602 | |
| Patel Snehal | GLSI | CEO and CFO | Apr 4 '25 | Buy | $8.73 | 5,500 | $48,015.00 | 5,570,602 |
Latest Greenwich LifeSciences Inc. News
GLSI Breaking Stock News: Dive into GLSI Ticker-Specific Updates for Smart Investing
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 04/23/2025
GlobeNewswire
2 months ago
Greenwich LifeSciences Provides Global Update on FLAMINGO-01
GlobeNewswire
2 months ago
Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial
MT Newswires
2 months ago
Greenwich LifeSciences Extends Lock-Up Period for Directors, Officers to March 2026
GlobeNewswire
2 months ago
Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026
MT Newswires
3 months ago
Greenwich LifeSciences Says Preliminary Safety Data for Breast Cancer Therapy Appears Consistent With Prior Trials
GlobeNewswire
3 months ago
Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01
Simply Wall St.
3 months ago
55% of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) is owned by insiders, and they've been buying recently
Compare GLSI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GLSI Greenwich LifeSciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.